<DOC>
	<DOCNO>NCT00003837</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Clinical trial study effectiveness 506U78 treat patient relapsed refractory T-cell acute lymphoblastic leukemia T-cell lymphoblastic lymphoma .</brief_summary>
	<brief_title>506U78 Treating Patients With Relapsed Refractory T-cell Acute Lymphoblastic Leukemia T-cell Lymphoblastic Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Provide investigational agent , 506U78 , physician management individual patient relapse refractory T-cell acute lymphoblastic ( lymphocytic ) leukemia T-cell lymphoblastic lymphoma candidate entry onto ongoing research clinical trial high priority . - Evaluate toxic effect 506U78 administer 2 hour IV infusion 3 day week every 21 day patient . - Evaluate antitumor efficacy regimen term rate complete responses patient . OUTLINE : Patients receive 506U78 2 hour day 1 , 3 , 5 . Treatment repeat every 21 day maximum 12 course absence unacceptable toxicity disease progression . Patients follow every 3 month one year every 6 month death . PROJECTED ACCRUAL : A minimum 25 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm relapsed refractory Tcell acute lymphoblastic leukemia Tcell lymphoblastic lymphoma Tumor cell exhibit phenotypic characteristic diseases No CNS involvement require intrathecal craniospinal radiotherapy Must eligible Intergroup , Cooperative Group , local research study higher priority PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 03 OR Karnofsky 40100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Other : No neuropathy grade 2 high No history significant neurological toxicity ( grade 2 great ) associate prior chemotherapy radiotherapy No active seizure disorder No active infection No active concurrent malignancy except curatively treat basal cell carcinoma carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Prior bone marrow transplantation allow No concurrent allogeneic bone marrow transplantation Chemotherapy : At least 3 week since prior chemotherapy ( 6 week nitrosourea mitomycin ) recover No prior 506U78 Endocrine therapy : No concurrent systemic steroid therapy Radiotherapy : See Disease Characteristics Prior radiotherapy allow Surgery : Not specify Other : No concurrent investigational therapy No concurrent treatment seizure</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>T-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
</DOC>